A meta-analysis confirms prior research suggesting exercise therapy benefits patients with knee and hip osteoarthritis (OA). The study found greater improvements in pain, function, performance and quality of life in patients with milder, as opposed to more severe, OA…
A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.
NEW YORK (Reuters Health)—Pregnancy outcomes in women with systemic lupus erythematosus (SLE) have improved markedly over the past two decades, although pregnancy risks remain higher than in women without lupus, according to a trends analysis. “Thirty years ago, most women with SLE were advised to avoid pregnancy because of high risks for maternal and fetal…
NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…
Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
New research recently found that, when combined with standard treatment, diet and exercise regimens are cost effective for overweight and obese patients with knee OA…
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…
Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…